Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Новые тенденции в лечении артериальной гипертонии 2013 года: ренессанс пульсового АД
Новые тенденции в лечении артериальной гипертонии 2013 года: ренессанс пульсового АД
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
В статье рассмотрены литературные данные о прогностическом значении высокого пульсового артериального давления. Приведены позиции европейских экспертов по роли пульсового артериального давления как маркера поражений огранов-мишеней артериальной гипертонии. Обсуждены возможности антигипертензивной терапии в снижении пульсового артериального давления.
Ключевые слова: артериальнаая гипертония, пульсовое артериальное давление, сердечно-сосудистые осложнения, антигипертензивная терапия, индапамид ретард.
Key words: arterial hypertension, pulse pressure, cardiovascular complications, antihypertensive therapy, indapamide retard.
Ключевые слова: артериальнаая гипертония, пульсовое артериальное давление, сердечно-сосудистые осложнения, антигипертензивная терапия, индапамид ретард.
________________________________________________
Key words: arterial hypertension, pulse pressure, cardiovascular complications, antihypertensive therapy, indapamide retard.
Полный текст
Список литературы
1. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension of the European Society of Hypertension: the Task Forse for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertension 2013; 31 (7): 1281–357.
2. European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011–53.
3. Mancia G, De Backer G, Dominiczak A et al. Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105–87.
4. Диагностика и лечение артериальной гипертензии. Российские рекомендации, 4-я редакция. Системные гипертензии. 2010; 3: 5–26.
5. Dyer AR, Stamler J, Shekelle RB et al. Pulse pressure III. Prognostic significance in four Chicago epidemiologic studies. J Chron Dis 1985; 35: 283–94.
6. Franklin S, Khan S, Wong ND et al. Is pulse pressure useful in predicting risk of coronary heart-disease? The Framingham Heart Study. Circulation 1999; 100: 354–60.
7. Franklin SS, Larson MG, Khan SA et al. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation 2001; 103 (9): 1245–9.
8. Assmann G, Cullen P, Evers T et al. Importance of arterial pulse pressure as a predictor of coronary heart disease risk in PROCAM. Eur Heart J 2005; 26 (20): 2120–6.
9. Verdecchia P, Schillaci G, Borgioni C et al. Ambulatory pulse pressure: a potent predictor of total cardiovascular risk in hypertension. Hypertension 1998; 32 (6): 983–8.
10. Vaccarino V, Holford TR, Krumholz HM. Pulse pressure and risk for myocardial infarction and heart failure in the elderly. J Am Coll Cardiol 2000; 36 (1): 130–8.
11. Franklin SS et al. Predictors of diastolic hypertension: The Framingham heart study. JACC 2004; 43: A444–449.
12. Fernаndez-Escribano Hernаndez M, Suаrez Fernаndez C, Sаez Vaquero T et al. Relationship between pulse pressure and clinical cardiovascular damage in elderly subjects of EPICARDIAN study. Rev Clin Esp 2007; 207 (6): 284–90.
13. Benetos A, Safar M, Rudnichi A et al. Pulse pressure: a predictor of long-term cardiovascular mortality in a French male population. Hypertension 1997; 30: 1410–5.
14. Nair GV, Chaput LA, Vittinghoff E, Herrington DM. Heart and Estrogen/Progestin Replacement Study Investigators. Pulse pressure and cardiovascular events in postmenopausal women with coronary heart disease. Chest 2005; 127 (5): 1498–506.
15. Alderman MH, Cohen H, Madhavan S, Kivilingh S. Serum uric acid and risk for cardiovascular events in successfully treated hypertensive patients. J Hypertens 1999; 34: 144–50.
16. Domanski MJ, Davis BR, Pfeffer MA et al. Isolated systolic hypertension: prognostic information provided by pulse pressure. Hypertension 1999; 34: 375–80.
17. Selker HP, Beshansky J, Schmid CH. Presenting pulse pressure predicts thrombolytic therapy-related intracranial hemorrhage. Thrombolytic predictive instrument (TPI) project result. Circulation 1994; 90: 1657–61.
18. Peters R, Beckett N, Fagard R et al. Increased pulse pressure linked to dementia: further results from the Hypertension in the Very Elderly Trial – HYVET. J Hypertens 2013; 31 (9): 1868–75.
19. Haider AW, Larson MG, Franklin SS, Levy D. Systolic Blood Pressure, Diastolic Blood Pressure, and Pulse Pressure as Predictors of Risk for Congestive Heart Failure in the Framingham Heart Study Ann Intern Med 2003; 138 (1): 10–6.
20. Chae CU, Pfeffer MA, Glynn RJ et al. Increased pulse pressure and risk of heart failure in the elderly. JAMA 1999; 281: 634–9.
21. Fesler P, Safar ME, du Cailar G et al. Pulse pressure is an independent determinant of renal function decline during treatment of essential hypertension. J Hypertens 2007; 25 (9): 1915–20.
22. Arulkumaran N, Diwakar R, Tahir Z et al. Pulse pressure and progression of chronic kidney disease. J Nephrol 2010; 23 (2): 189–93.
23. Briet M et al. Longitudinal study: Central pulse pressure is an independent determinant of end stage renal desease. JASN 2011.
24. Perry M, Miller P, Fornoff J et al. Early predictor of 15-year end-stage renal disease in hypertensive patients. Hypertension 1995; 25 (Pt. I): 587–94.
25. Lee ML, Rosner BA, Weiss ST. Relationship of blood pressure to cardiovascular death: the effects of pulse pressure in the elderly. Ann Epidemiology 1999; 9: 101–7.
26. Domanski ML, Mitchell GF, Norman JE et al. Independent prognostic information provided by sphygmomanometrically determined pulse pressure and mean arterial pressure in patients with left ventricular dysfunction. J Am Coll Cardiol 1999; 33: 951–8.
27. Abernethy J, Borhani NO, Hawkins CM et al. Systolic blood pressure as an independent predictor of mortality in the Hypertension Detection and Follow-up Program. Am J Prev Med 1986; 2: 123–32.
28. Alderman MH, Cohen H, Madhavan S. Distribution and determinants of cardiovascular events during 20 years of successful antihypertensive treatment. J Hypertension 1998; 16: 761–9.
29. London G, Schmieder R, Calvo C, Asmar R. Indapamide SR versus candesartan and amlodipine in hypertension: The X-CELLENT study. Am J Hypertens 2006; 19: 113–21.
30. Nedogoda S. Indapamide SR versus hydrochlortiazide for the treatment of systolic hypertension in older people. Eur Heart J 2005; 26: 612.
31. Глезер М.Г. Пульсовое АД: почему это важно? М.: Медиком, 2013; c. 1.
32. Мартынов А.И., Терновой С.К., Остроумова О.Д. и др. Особенности изменения растяжимости аорты у пожилых больных на фоне длительной терапии различными классами гипотензивных средств (по данным магнитно-резонанстной томографии) Кардиология. 2002; 42 (5): 19–22.
33. Сайгитов Р.Т., Глезер М.Г. Мета-аналитический подход в изучении антигипертензивной эффективности индапамида с контролируемым высвобождением в терапии больных с артериальной гипертензией (по данным открытых исследований). Артериальная гипертензия. 2010; 16 (1): 52–61.
34. Del Rio M, Chulia T, Merchan-Perez A et al. Effects of indapamide on atherosclerosis development in cholesterol-fed rabbits. J Cardiovasc Pharmacol 1995; 25 (6): 973–8.
2. European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011–53.
3. Mancia G, De Backer G, Dominiczak A et al. Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105–87.
4. Диагностика и лечение артериальной гипертензии. Российские рекомендации, 4-я редакция. Системные гипертензии. 2010; 3: 5–26.
5. Dyer AR, Stamler J, Shekelle RB et al. Pulse pressure III. Prognostic significance in four Chicago epidemiologic studies. J Chron Dis 1985; 35: 283–94.
6. Franklin S, Khan S, Wong ND et al. Is pulse pressure useful in predicting risk of coronary heart-disease? The Framingham Heart Study. Circulation 1999; 100: 354–60.
7. Franklin SS, Larson MG, Khan SA et al. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation 2001; 103 (9): 1245–9.
8. Assmann G, Cullen P, Evers T et al. Importance of arterial pulse pressure as a predictor of coronary heart disease risk in PROCAM. Eur Heart J 2005; 26 (20): 2120–6.
9. Verdecchia P, Schillaci G, Borgioni C et al. Ambulatory pulse pressure: a potent predictor of total cardiovascular risk in hypertension. Hypertension 1998; 32 (6): 983–8.
10. Vaccarino V, Holford TR, Krumholz HM. Pulse pressure and risk for myocardial infarction and heart failure in the elderly. J Am Coll Cardiol 2000; 36 (1): 130–8.
11. Franklin SS et al. Predictors of diastolic hypertension: The Framingham heart study. JACC 2004; 43: A444–449.
12. Fernаndez-Escribano Hernаndez M, Suаrez Fernаndez C, Sаez Vaquero T et al. Relationship between pulse pressure and clinical cardiovascular damage in elderly subjects of EPICARDIAN study. Rev Clin Esp 2007; 207 (6): 284–90.
13. Benetos A, Safar M, Rudnichi A et al. Pulse pressure: a predictor of long-term cardiovascular mortality in a French male population. Hypertension 1997; 30: 1410–5.
14. Nair GV, Chaput LA, Vittinghoff E, Herrington DM. Heart and Estrogen/Progestin Replacement Study Investigators. Pulse pressure and cardiovascular events in postmenopausal women with coronary heart disease. Chest 2005; 127 (5): 1498–506.
15. Alderman MH, Cohen H, Madhavan S, Kivilingh S. Serum uric acid and risk for cardiovascular events in successfully treated hypertensive patients. J Hypertens 1999; 34: 144–50.
16. Domanski MJ, Davis BR, Pfeffer MA et al. Isolated systolic hypertension: prognostic information provided by pulse pressure. Hypertension 1999; 34: 375–80.
17. Selker HP, Beshansky J, Schmid CH. Presenting pulse pressure predicts thrombolytic therapy-related intracranial hemorrhage. Thrombolytic predictive instrument (TPI) project result. Circulation 1994; 90: 1657–61.
18. Peters R, Beckett N, Fagard R et al. Increased pulse pressure linked to dementia: further results from the Hypertension in the Very Elderly Trial – HYVET. J Hypertens 2013; 31 (9): 1868–75.
19. Haider AW, Larson MG, Franklin SS, Levy D. Systolic Blood Pressure, Diastolic Blood Pressure, and Pulse Pressure as Predictors of Risk for Congestive Heart Failure in the Framingham Heart Study Ann Intern Med 2003; 138 (1): 10–6.
20. Chae CU, Pfeffer MA, Glynn RJ et al. Increased pulse pressure and risk of heart failure in the elderly. JAMA 1999; 281: 634–9.
21. Fesler P, Safar ME, du Cailar G et al. Pulse pressure is an independent determinant of renal function decline during treatment of essential hypertension. J Hypertens 2007; 25 (9): 1915–20.
22. Arulkumaran N, Diwakar R, Tahir Z et al. Pulse pressure and progression of chronic kidney disease. J Nephrol 2010; 23 (2): 189–93.
23. Briet M et al. Longitudinal study: Central pulse pressure is an independent determinant of end stage renal desease. JASN 2011.
24. Perry M, Miller P, Fornoff J et al. Early predictor of 15-year end-stage renal disease in hypertensive patients. Hypertension 1995; 25 (Pt. I): 587–94.
25. Lee ML, Rosner BA, Weiss ST. Relationship of blood pressure to cardiovascular death: the effects of pulse pressure in the elderly. Ann Epidemiology 1999; 9: 101–7.
26. Domanski ML, Mitchell GF, Norman JE et al. Independent prognostic information provided by sphygmomanometrically determined pulse pressure and mean arterial pressure in patients with left ventricular dysfunction. J Am Coll Cardiol 1999; 33: 951–8.
27. Abernethy J, Borhani NO, Hawkins CM et al. Systolic blood pressure as an independent predictor of mortality in the Hypertension Detection and Follow-up Program. Am J Prev Med 1986; 2: 123–32.
28. Alderman MH, Cohen H, Madhavan S. Distribution and determinants of cardiovascular events during 20 years of successful antihypertensive treatment. J Hypertension 1998; 16: 761–9.
29. London G, Schmieder R, Calvo C, Asmar R. Indapamide SR versus candesartan and amlodipine in hypertension: The X-CELLENT study. Am J Hypertens 2006; 19: 113–21.
30. Nedogoda S. Indapamide SR versus hydrochlortiazide for the treatment of systolic hypertension in older people. Eur Heart J 2005; 26: 612.
31. Глезер М.Г. Пульсовое АД: почему это важно? М.: Медиком, 2013; c. 1.
32. Мартынов А.И., Терновой С.К., Остроумова О.Д. и др. Особенности изменения растяжимости аорты у пожилых больных на фоне длительной терапии различными классами гипотензивных средств (по данным магнитно-резонанстной томографии) Кардиология. 2002; 42 (5): 19–22.
33. Сайгитов Р.Т., Глезер М.Г. Мета-аналитический подход в изучении антигипертензивной эффективности индапамида с контролируемым высвобождением в терапии больных с артериальной гипертензией (по данным открытых исследований). Артериальная гипертензия. 2010; 16 (1): 52–61.
34. Del Rio M, Chulia T, Merchan-Perez A et al. Effects of indapamide on atherosclerosis development in cholesterol-fed rabbits. J Cardiovasc Pharmacol 1995; 25 (6): 973–8.
2. European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011–53.
3. Mancia G, De Backer G, Dominiczak A et al. Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105–87.
4. Диагностика и лечение артериальной гипертензии. Российские рекомендации, 4-я редакция. Системные гипертензии. 2010; 3: 5–26.
5. Dyer AR, Stamler J, Shekelle RB et al. Pulse pressure III. Prognostic significance in four Chicago epidemiologic studies. J Chron Dis 1985; 35: 283–94.
6. Franklin S, Khan S, Wong ND et al. Is pulse pressure useful in predicting risk of coronary heart-disease? The Framingham Heart Study. Circulation 1999; 100: 354–60.
7. Franklin SS, Larson MG, Khan SA et al. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation 2001; 103 (9): 1245–9.
8. Assmann G, Cullen P, Evers T et al. Importance of arterial pulse pressure as a predictor of coronary heart disease risk in PROCAM. Eur Heart J 2005; 26 (20): 2120–6.
9. Verdecchia P, Schillaci G, Borgioni C et al. Ambulatory pulse pressure: a potent predictor of total cardiovascular risk in hypertension. Hypertension 1998; 32 (6): 983–8.
10. Vaccarino V, Holford TR, Krumholz HM. Pulse pressure and risk for myocardial infarction and heart failure in the elderly. J Am Coll Cardiol 2000; 36 (1): 130–8.
11. Franklin SS et al. Predictors of diastolic hypertension: The Framingham heart study. JACC 2004; 43: A444–449.
12. Fernаndez-Escribano Hernаndez M, Suаrez Fernаndez C, Sаez Vaquero T et al. Relationship between pulse pressure and clinical cardiovascular damage in elderly subjects of EPICARDIAN study. Rev Clin Esp 2007; 207 (6): 284–90.
13. Benetos A, Safar M, Rudnichi A et al. Pulse pressure: a predictor of long-term cardiovascular mortality in a French male population. Hypertension 1997; 30: 1410–5.
14. Nair GV, Chaput LA, Vittinghoff E, Herrington DM. Heart and Estrogen/Progestin Replacement Study Investigators. Pulse pressure and cardiovascular events in postmenopausal women with coronary heart disease. Chest 2005; 127 (5): 1498–506.
15. Alderman MH, Cohen H, Madhavan S, Kivilingh S. Serum uric acid and risk for cardiovascular events in successfully treated hypertensive patients. J Hypertens 1999; 34: 144–50.
16. Domanski MJ, Davis BR, Pfeffer MA et al. Isolated systolic hypertension: prognostic information provided by pulse pressure. Hypertension 1999; 34: 375–80.
17. Selker HP, Beshansky J, Schmid CH. Presenting pulse pressure predicts thrombolytic therapy-related intracranial hemorrhage. Thrombolytic predictive instrument (TPI) project result. Circulation 1994; 90: 1657–61.
18. Peters R, Beckett N, Fagard R et al. Increased pulse pressure linked to dementia: further results from the Hypertension in the Very Elderly Trial – HYVET. J Hypertens 2013; 31 (9): 1868–75.
19. Haider AW, Larson MG, Franklin SS, Levy D. Systolic Blood Pressure, Diastolic Blood Pressure, and Pulse Pressure as Predictors of Risk for Congestive Heart Failure in the Framingham Heart Study Ann Intern Med 2003; 138 (1): 10–6.
20. Chae CU, Pfeffer MA, Glynn RJ et al. Increased pulse pressure and risk of heart failure in the elderly. JAMA 1999; 281: 634–9.
21. Fesler P, Safar ME, du Cailar G et al. Pulse pressure is an independent determinant of renal function decline during treatment of essential hypertension. J Hypertens 2007; 25 (9): 1915–20.
22. Arulkumaran N, Diwakar R, Tahir Z et al. Pulse pressure and progression of chronic kidney disease. J Nephrol 2010; 23 (2): 189–93.
23. Briet M et al. Longitudinal study: Central pulse pressure is an independent determinant of end stage renal desease. JASN 2011.
24. Perry M, Miller P, Fornoff J et al. Early predictor of 15-year end-stage renal disease in hypertensive patients. Hypertension 1995; 25 (Pt. I): 587–94.
25. Lee ML, Rosner BA, Weiss ST. Relationship of blood pressure to cardiovascular death: the effects of pulse pressure in the elderly. Ann Epidemiology 1999; 9: 101–7.
26. Domanski ML, Mitchell GF, Norman JE et al. Independent prognostic information provided by sphygmomanometrically determined pulse pressure and mean arterial pressure in patients with left ventricular dysfunction. J Am Coll Cardiol 1999; 33: 951–8.
27. Abernethy J, Borhani NO, Hawkins CM et al. Systolic blood pressure as an independent predictor of mortality in the Hypertension Detection and Follow-up Program. Am J Prev Med 1986; 2: 123–32.
28. Alderman MH, Cohen H, Madhavan S. Distribution and determinants of cardiovascular events during 20 years of successful antihypertensive treatment. J Hypertension 1998; 16: 761–9.
29. London G, Schmieder R, Calvo C, Asmar R. Indapamide SR versus candesartan and amlodipine in hypertension: The X-CELLENT study. Am J Hypertens 2006; 19: 113–21.
30. Nedogoda S. Indapamide SR versus hydrochlortiazide for the treatment of systolic hypertension in older people. Eur Heart J 2005; 26: 612.
31. Глезер М.Г. Пульсовое АД: почему это важно? М.: Медиком, 2013; c. 1.
32. Мартынов А.И., Терновой С.К., Остроумова О.Д. и др. Особенности изменения растяжимости аорты у пожилых больных на фоне длительной терапии различными классами гипотензивных средств (по данным магнитно-резонанстной томографии) Кардиология. 2002; 42 (5): 19–22.
33. Сайгитов Р.Т., Глезер М.Г. Мета-аналитический подход в изучении антигипертензивной эффективности индапамида с контролируемым высвобождением в терапии больных с артериальной гипертензией (по данным открытых исследований). Артериальная гипертензия. 2010; 16 (1): 52–61.
34. Del Rio M, Chulia T, Merchan-Perez A et al. Effects of indapamide on atherosclerosis development in cholesterol-fed rabbits. J Cardiovasc Pharmacol 1995; 25 (6): 973–8.
________________________________________________
2. European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011–53.
3. Mancia G, De Backer G, Dominiczak A et al. Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105–87.
4. Диагностика и лечение артериальной гипертензии. Российские рекомендации, 4-я редакция. Системные гипертензии. 2010; 3: 5–26.
5. Dyer AR, Stamler J, Shekelle RB et al. Pulse pressure III. Prognostic significance in four Chicago epidemiologic studies. J Chron Dis 1985; 35: 283–94.
6. Franklin S, Khan S, Wong ND et al. Is pulse pressure useful in predicting risk of coronary heart-disease? The Framingham Heart Study. Circulation 1999; 100: 354–60.
7. Franklin SS, Larson MG, Khan SA et al. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation 2001; 103 (9): 1245–9.
8. Assmann G, Cullen P, Evers T et al. Importance of arterial pulse pressure as a predictor of coronary heart disease risk in PROCAM. Eur Heart J 2005; 26 (20): 2120–6.
9. Verdecchia P, Schillaci G, Borgioni C et al. Ambulatory pulse pressure: a potent predictor of total cardiovascular risk in hypertension. Hypertension 1998; 32 (6): 983–8.
10. Vaccarino V, Holford TR, Krumholz HM. Pulse pressure and risk for myocardial infarction and heart failure in the elderly. J Am Coll Cardiol 2000; 36 (1): 130–8.
11. Franklin SS et al. Predictors of diastolic hypertension: The Framingham heart study. JACC 2004; 43: A444–449.
12. Fernаndez-Escribano Hernаndez M, Suаrez Fernаndez C, Sаez Vaquero T et al. Relationship between pulse pressure and clinical cardiovascular damage in elderly subjects of EPICARDIAN study. Rev Clin Esp 2007; 207 (6): 284–90.
13. Benetos A, Safar M, Rudnichi A et al. Pulse pressure: a predictor of long-term cardiovascular mortality in a French male population. Hypertension 1997; 30: 1410–5.
14. Nair GV, Chaput LA, Vittinghoff E, Herrington DM. Heart and Estrogen/Progestin Replacement Study Investigators. Pulse pressure and cardiovascular events in postmenopausal women with coronary heart disease. Chest 2005; 127 (5): 1498–506.
15. Alderman MH, Cohen H, Madhavan S, Kivilingh S. Serum uric acid and risk for cardiovascular events in successfully treated hypertensive patients. J Hypertens 1999; 34: 144–50.
16. Domanski MJ, Davis BR, Pfeffer MA et al. Isolated systolic hypertension: prognostic information provided by pulse pressure. Hypertension 1999; 34: 375–80.
17. Selker HP, Beshansky J, Schmid CH. Presenting pulse pressure predicts thrombolytic therapy-related intracranial hemorrhage. Thrombolytic predictive instrument (TPI) project result. Circulation 1994; 90: 1657–61.
18. Peters R, Beckett N, Fagard R et al. Increased pulse pressure linked to dementia: further results from the Hypertension in the Very Elderly Trial – HYVET. J Hypertens 2013; 31 (9): 1868–75.
19. Haider AW, Larson MG, Franklin SS, Levy D. Systolic Blood Pressure, Diastolic Blood Pressure, and Pulse Pressure as Predictors of Risk for Congestive Heart Failure in the Framingham Heart Study Ann Intern Med 2003; 138 (1): 10–6.
20. Chae CU, Pfeffer MA, Glynn RJ et al. Increased pulse pressure and risk of heart failure in the elderly. JAMA 1999; 281: 634–9.
21. Fesler P, Safar ME, du Cailar G et al. Pulse pressure is an independent determinant of renal function decline during treatment of essential hypertension. J Hypertens 2007; 25 (9): 1915–20.
22. Arulkumaran N, Diwakar R, Tahir Z et al. Pulse pressure and progression of chronic kidney disease. J Nephrol 2010; 23 (2): 189–93.
23. Briet M et al. Longitudinal study: Central pulse pressure is an independent determinant of end stage renal desease. JASN 2011.
24. Perry M, Miller P, Fornoff J et al. Early predictor of 15-year end-stage renal disease in hypertensive patients. Hypertension 1995; 25 (Pt. I): 587–94.
25. Lee ML, Rosner BA, Weiss ST. Relationship of blood pressure to cardiovascular death: the effects of pulse pressure in the elderly. Ann Epidemiology 1999; 9: 101–7.
26. Domanski ML, Mitchell GF, Norman JE et al. Independent prognostic information provided by sphygmomanometrically determined pulse pressure and mean arterial pressure in patients with left ventricular dysfunction. J Am Coll Cardiol 1999; 33: 951–8.
27. Abernethy J, Borhani NO, Hawkins CM et al. Systolic blood pressure as an independent predictor of mortality in the Hypertension Detection and Follow-up Program. Am J Prev Med 1986; 2: 123–32.
28. Alderman MH, Cohen H, Madhavan S. Distribution and determinants of cardiovascular events during 20 years of successful antihypertensive treatment. J Hypertension 1998; 16: 761–9.
29. London G, Schmieder R, Calvo C, Asmar R. Indapamide SR versus candesartan and amlodipine in hypertension: The X-CELLENT study. Am J Hypertens 2006; 19: 113–21.
30. Nedogoda S. Indapamide SR versus hydrochlortiazide for the treatment of systolic hypertension in older people. Eur Heart J 2005; 26: 612.
31. Глезер М.Г. Пульсовое АД: почему это важно? М.: Медиком, 2013; c. 1.
32. Мартынов А.И., Терновой С.К., Остроумова О.Д. и др. Особенности изменения растяжимости аорты у пожилых больных на фоне длительной терапии различными классами гипотензивных средств (по данным магнитно-резонанстной томографии) Кардиология. 2002; 42 (5): 19–22.
33. Сайгитов Р.Т., Глезер М.Г. Мета-аналитический подход в изучении антигипертензивной эффективности индапамида с контролируемым высвобождением в терапии больных с артериальной гипертензией (по данным открытых исследований). Артериальная гипертензия. 2010; 16 (1): 52–61.
34. Del Rio M, Chulia T, Merchan-Perez A et al. Effects of indapamide on atherosclerosis development in cholesterol-fed rabbits. J Cardiovasc Pharmacol 1995; 25 (6): 973–8.
Авторы
О.Д.Остроумова*1, 2, Н.Ю.Галеева3
1 ГБОУ ВПО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава России;
2 ГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава России;
3 ГБУЗ Городская клиническая больница №70 Департамента здравоохранения г. Москвы
*ostroumova.olga@mail.ru
*ostroumova.olga@mail.ru
1 ГБОУ ВПО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава России;
2 ГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава России;
3 ГБУЗ Городская клиническая больница №70 Департамента здравоохранения г. Москвы
*ostroumova.olga@mail.ru
________________________________________________
*ostroumova.olga@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.